Kyverna Therapeutics, Inc. KYTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $126.36M-0.8% | $133.72M+18.9% | $137.19M+42.7% | $135.93M+68.6% | $127.43M+100% | ||
| $37.43M+12.6% | $36.11M+19.8% | $34.4M+28.4% | $35.7M+79.9% | $33.22M+99.8% | ||
| $163.79M+1.9% | $169.83M+19.1% | $171.59M+39.6% | $171.63M+70.9% | $160.65M+100% | ||
| -$163.79M-1.9% | -$169.83M-19.1% | -$171.59M-39.6% | -$171.63M-70.9% | -$160.65M-100% | ||
| $1.13M+820% | $490K+245% | $73K-54.9% | $98K-45.6% | $123K-34.2% | ||
| $7.39M-51.5% | $8.52M-43.7% | $10.59M-13.8% | $12.93M+46.6% | $15.24M+246% | ||
| -$156.4M-7.6% | -$161.31M-26.5% | -$160.99M-45.5% | -$158.7M-73.2% | -$145.42M-91.6% | ||
| -$3.27+3.3% | -$3.64-4.9% | -$3.73+87.3% | -$3.68+92.9% | -$3.38+95.3% | ||
| -$162.14M-2.3% | -$168.03M-19.6% | -$169.59M-40.3% | -$169.49M-72.0% | -$158.5M-102% | ||
| -$163.79M-1.9% | -$169.83M-19.1% | -$171.59M-39.6% | -$171.63M-70.9% | -$160.65M-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kyverna Therapeutics, Inc. profitable?
- Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s earnings per share?
- Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.
- Where does Kyverna Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.